Coloplast AS v Macgregor Healthcare Ltd
Decision date: 24 October 2018
Neutral citation: [2018] EWHC 2797 (IPEC)
Overall AI summary confidence: high
Short overview
This short overview is intended to summarise the case, issues and outcome so far as they are supported by the judgment.
AI confidence in this short overview: high
This case concerned Coloplast's patent for a ready-to-use hydrophilic-coated urinary catheter assembly and MacGregor's challenge to its validity and alleged infringement. The court construed key terms (holding “catheter” covers intermittent and indwelling types, and “prior to use” can include activation during manufacture but excludes a separate sealed ampoule), found the claims novel but invalid for lack of inventive step and for insufficiency, and would have found infringement if the patent had been valid.
Ratio decidendi
This summary is intended to identify the ratio decidendi, meaning the legal reasons for deciding and the binding part of the decision.
AI confidence in this ratio decidendi summary: medium
The dispositive reasoning is that claims must be construed as a skilled reader would in context, so broad descriptive terms are given their ordinary scope; where the specification presents multiple embodiments, wording such as “prior to use” can include activation in manufacture. A claim is invalid for insufficiency if the specification, together with common general knowledge, does not enable the skilled team to perform the invention across the full breadth of the claims without undue burden. Applying these principles, the asserted claims were obvious over the cited prior art and insufficiently disclosed.
Obiter dicta
This summary is intended to identify obiter dicta, meaning observations made by the way that were not necessary to deciding the case and are not binding.
AI confidence in this obiter dicta summary: medium
The judge made remarks about disclosure practice in IPEC proceedings, warning that courts should be cautious about ordering or permitting disclosure beyond appropriate limits and should guard against overbroad disclosure practices — guidance not essential to the decision on validity.